논문 상세보기

원헬스(One Health) 관점의 전파차단형 SFTS 반려동물 백신: 개발현황과 상용화 과제(총설) KCI 등재

Transmission-Blocking SFTS Vaccines for Companion Animals from One Health Perspective: Development Status and Challenges for Commercialization (Review)

신채이, 유지혜, 이현주, 이성진
  • 언어KOR
  • URLhttps://db.koreascholar.com/Article/Detail/453415
구독 기관 인증 시 무료 이용이 가능합니다. 4,200원
동물자원연구 (Annals of Animal Resources Sciences)
강원대학교 동물자원공동연구소 (Institute of Animal Resources Kangwon National University)
초록

Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne zoonosis whose public health risk is increasingly shaped by an expanding “tick–companion animal–human” transmission cycle. This study aimed to frame vaccination of companion animals as a One Health, transmission-blocking intervention and to identify the scientific and product-development bottlenecks that have delayed commercialization. We conducted (i) a structured narrative review of preclinical SFTS vaccine candidates across major platforms, including DNA vaccines, viral-vectored vaccines, live-attenuated vaccines, recombinant protein vaccines, lipid nanoparticle (LNP)-mRNA vaccines, and replicating RNA vaccines, and (ii) a cross-sectional survey of pet owners to assess disease awareness and vaccine acceptance. The survey revealed a clear implementation gap: while most respondents reported low awareness of SFTS, willingness to vaccinate companion animals was comparatively high, indicating substantial unmet demand. Across platforms, preclinical studies demonstrate protective efficacy, but practical translation is constrained by platform-specific barriers such as device-dependent delivery, biosafety concerns, limitations in inducing sterilizing immunity, and challenges in formulation stability, cold-chain logistics, and scalable manufacturing. We propose that target product profiles for veterinary SFTS vaccines should prioritize reduction or elimination of viremia and viral shedding as primary endpoints, rather than survival alone, to effectively interrupt spillover risk. Advancing candidates that meet these transmission-blocking criteria while resolving deployment and manufacturing constraints will be critical to achieving commercialization and establishing a durable immune barrier in companion animals

키워드
One HealthSFTSTransmission-blocking vaccineCompanion animalsVaccine Commercialization
목차
ABSTRACT
Ⅰ. 서론
Ⅱ. 본론
    1. 방어 면역의 핵심 타겟: 바이러스 표면 당단백질(Gn/Gc)
    2. 백신 플랫폼별 개발 현황
    3. 상용화 병목 축 (안전성·현장성·유통/제조·효능지표)기반 비교
    4. 전임상 효능 평가: 면역학적 기전과 살균 방어
Ⅲ. 결론
Ⅳ. 요약
사사
Ⅴ. 참고문헌
저자
  • 신채이(강원대학교 동물생명과학대학 대학생) | Chae Yi Shin (Undergraduate Student, College of Animal Life Sciences, Kangwon National University, Chuncheon 24341, Korea)
  • 유지혜(강원대학교 동물생명과학대학 대학생) | Ji Hye Yu (Undergraduate Student, College of Animal Life Sciences, Kangwon National University, Chuncheon 24341, Korea)
  • 이현주(강원대학교 동물생명과학대학 대학생) | Hyun Joo Lee (Undergraduate Student, College of Animal Life Sciences, Kangwon National University, Chuncheon 24341, Korea)
  • 이성진(강원대학교 동물생명과학대학 교수) | Sung-Jin Lee (Professor, College of Animal Life Sciences, Kangwon National University, Chuncheon 24341, Korea) Corresponding author